1. < Home

Hematology/Oncology

Poison With a Purpose: A Case Report on Arsenic Cardiotoxicity and Obesity

Nachtigal EA, Doan TN. Poison With a Purpose: A Case Report on Arsenic Cardiotoxicity and Obesity. Cureus. 2022 Dec 31;14(12):e33185. doi: 10.7759/cureus.33185. PMID: 36726885; PMCID:[...]

By sjmartinez • February 3, 2023
Multimodality Therapies for Localized Prostate Cancer

Valle LF, Jiang T, Weiner AB, Reiter RE, Rettig MB, Shen J, Chang AJ, Nickols NG, Steinberg ML, Kishan AU. Multimodality Therapies for Localized Prostate[...]

By sjmartinez • February 2, 2023
First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817

Ready NE, Audigier-Valette C, Goldman JW, Felip E, Ciuleanu TE, Rosario García Campelo M, Jao K, Barlesi F, Bordenave S, Rijavec E, Urban L, Aucoin[...]

By sjmartinez • February 2, 2023
Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial

Herbst RS, Wu YL, John T, Grohe C, Majem M, Wang J, Kato T, Goldman JW, Laktionov K, Kim SW, Yu CJ, Vu HV, Lu[...]

By sjmartinez • February 1, 2023
Proteome analysis of monocytes implicates altered mitochondrial biology in adults reporting adverse childhood experiences

Zang JCS, May C, Hellwig B, Moser D, Hengstler JG, Cole S, Heinrichs M, Rahnenführer J, Marcus K, Kumsta R. Proteome analysis of monocytes implicates[...]

By sjmartinez • February 1, 2023
Open-label, Phase 2 study of roxadustat for the treatment of anemia in patients receiving chemotherapy for non-myeloid malignancies

Glaspy J, Gabrail NY, Locantore-Ford P, Lee T, Modelska K, Samal V, Henry DH. Open-label, Phase 2 study of roxadustat for the treatment of anemia[...]

By sjmartinez • January 31, 2023
Year 2. January 30. Research, Scholarship, and Advocacy form the Lab to Society

One of the more satisfying aspects of my job is seeing the breadth and impact of the scholarship, research and scientific accomplishments of so many[...]

By sjmartinez • January 30, 2023
Results of TRIO-15, a multicenter, open-label, phase II study of the efficacy and safety of ganitumab in patients with recurrent platinum-sensitive ovarian cancer

Davidson TM, Lebreton CL, Hendricksen AEW, Atkinson HJ, Larson MC, Oberg AL, Provencher DM, Glaspy JA, Karlan BY, Slamon DJ, Konecny GE, Ray-Coquard IL. Results[...]

By sjmartinez • January 30, 2023
Final findings from the CONTROL trial: Strategies to reduce the incidence and severity of neratinib-associated diarrhea in patients with HER2-positive early-stage breast cancer

Chan A, Ruiz-Borrego M, Marx G, Chien AJ, Rugo HS, Brufsky A, Thirlwell M, Trudeau M, Bose R, García-Sáenz JA, Egle D, Pistilli B, Wassermann[...]

By sjmartinez • January 27, 2023
Aggregation tests identify new gene associations with breast cancer in populations with diverse ancestry

Mueller SH, Lai AG, Valkovskaya M, Michailidou K, Bolla MK, Wang Q, Dennis J, Lush M, Abu-Ful Z, Ahearn TU, Andrulis IL, Anton-Culver H, Antonenkova[...]

By sjmartinez • January 27, 2023